Table 2.
Outcomes and complications in MIC patients compared to transplanted controls out to year 5.
| Controls (N = 15) |
MIC | P A | |||
|---|---|---|---|---|---|
| Group A, B (N = 6) |
Group C (N = 4) |
Total cohort (N = 10) |
|||
| Pat. with BCR – N (%) Rejection episodes – N Acute TCMR (≥BANFF IA) Chronic active TCMR Acute ABMR Chronic active ABMR |
1 (7) 1 0 0 0 1 |
1 (17) 1 0 1 0 0 |
0 (0) 0 0 0 0 0 |
1 (10) 1 0 1 0 0 |
1.0 |
| Pat. with de novo DSA – N (%) | 5 (33) | 0 (0) | 0 (0) | 0 (0) | 0.061 |
| Pat. with DGF – N (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1.0 |
| Pat. with opportunistic infections – N (%) Infectious episodes – N Pneumonia CMV reactivation > 1,000 IU/mL BKV replication > 10,000 copies/mL BKV-associated nephropathy Other |
8 (53) 13 4 4 2 0 3 |
1 (17)B
1B 0 1B 0 0 0 |
0 (0) 0 0 0 0 0 0 |
1 (10)B
1B 0 1B 0 0 0 |
0.041 |
| Pat. with non-opportunistic infections – N (%) Infectious episodes – N CVC-associated infection Urinary tract infection Post-operative wound infection Pneumonia Influenza A/B, COVID-19 Other or unknown |
13 (87) 43 1 16 1 7 3 15 |
4 (67) 9 1 6 0 0 1 1 |
3 (75) 15 0 8 1 1 1 4 |
7 (70) 24 1 14 1 1 2 5 |
0.36 |
| Pat. with multi-resistant bacteria – N (%) | 3 (20) | 0 (0) | 0 (0) | 0 (0) | 0.25 |
| Pat. with rehospitalization – N (%) Total rehospitalizations – N |
12 (80) 38 |
6 (100) 10 |
4 (100) 16 |
10 (100) 26 |
0.25 |
| Pat. with PTLD or malignancy – N (%) | 1 (7) | 0 (0) | 0 (0) | 0 (0) | 1.0 |
| Pat. with cardiovascular events – N (%) | 1 (7) | 0 (0) | 0 (0) | 0 (0) | 1.0 |
| Pat. with surgical complicationsC – N (%) Bleeding Wound healing disturbances Urinary leakage or stenosis Lymphocele Hernia Other |
6 (40) 0 0 2 2 1 1 |
2 (33) 0 2 0 0 0 0 |
2 (50) 1 0 1 0 0 0 |
4 (40) 1 2 1 0 0 0 |
1.0 |
| Total antihypertensive therapeutic intensity score (TIS) – median (range) | |||||
| Year 1 Year 3 Year 5 |
0.9 (0-2.8) 1.0 (0-2.3) 0.9 (0-2.5) |
1.1 (0.3-1.5) 1.1 (0.3-1.8) 1.3 (0.3-1.8) |
1.0 (0.2-3.0) 1.0 (0.4-2.5) 1.5 (0.4-2.8) |
1.0 (0.2-3.0) 1.0 (0.3-2.5) 1.3 (0.3-2.8) |
0.94 0.87 0.65 |
| NODATC – N (%) | 2 (13) | 0 (0) | 0 (0) | 0 (0) | 0.50 |
AFor the comparison of MIC patients, Total cohort (N = 10) versus Controls (N = 15). BThis episode was identified retrospectively during review of a letter from the primary physician. CMV reactivation had resolved without treatment. CRequiring treatment. ABMR, antibody-mediated rejection; BCR, biopsy-confirmed rejection; BKV, BK virus; CMV, cytomegalovirus; CVC, central venous catheter; DGF, delayed graft function; DSA, donor-specific HLA-A, -B, -DR, -DQ antibodies at a cutoff of 1,000 MFI; NODAT, new-onset diabetes after transplantation; PTLD, post-transplant lymphoproliferative disease; TCMR, T-cell-mediated rejection.